Get started

ACHN

$ACHN A Breakout Buy Above $5About Achillion Pharmaceuticals Achillion Pharmaceuticals, Inc. (ACHN) is a clinical-stage biopharmaceutical company focused on advancing its oral small molecule complement inhibitors into late-stage development and commercialization. Research has shown that an overactive complement system plays a critical role in multiple disease conditions including the therapeutic areas of nephrology, hematology, ophthalmology and neurology. Achillion is initially focusing its drug development activities on complement-mediated diseases where there are no approved therapies or significant unmet medical needs persist despite existing therapies. Potential indications being evaluated for its compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN). Each of the product candidates in the Company’s oral small molecule portfolio was discovered in its laboratories and is wholly owned. In its efforts to advance its investigational product candidates into registrational clinical trials and commercialization, the Company plans to work closely with key stakeholders including patients, payors, regulators, and healthcare providers.
ALong
by InsiderFinancial
DSKX Begins To Rally After The Conference CallShares of DSKX continues to rally from last week after they held a conference call to discuss the recently announced agreement to acquire Radiancy, Inc., a leading developer of consumer medical devices and the Neova® dermatological products. It appears investors are beginning to notice the financial value this new deal brings and the future outlook of the company, so if you haven't already, I highly encourage you to listen to today's conference call as soon as possible. Much larger company structure overall, significant increase in revenue, assets, cash flow and working capital with a very reputable management team to move the company forward. The fact that the current market cap is only 33M is what really gets me excited. Listen to the call to learn more: The replay of the conference call can be heard by dialing 1-888-286-8010 in the United States and Canada or +1-617-801-6888 internationally, then referencing the Conference Passcode "56187013" A recording of the call can also be heard on the company website. In the call, the DS Healthcare Group management team shared their motivations and answered questions relating to the business fundamentals on the Radiancy & Neova® deal, explaining how natural strategy alignment and synergies will lead to significant bottom line contribution. The call was hosted by Mark Brockelman (CFO), Manny Gonzeles (CCO) and Renee Barch-Niles (CEO) and took place on Thursday, February 25th, 2016, at 8:30 a.m. EST. -Renee Barch-Niles (CEO), an experienced CPG Executive who drove double-digit year-over-year growth in global food, drug, mass, club and specialty channels for Global companies such as Daymon Worldwide and Emilia Personal Care. -Mark Brockelman (CFO) who has great experience in mergers and acquisitions, systems integration expertise and highly astute financial acumen. Mr. Brockelman Brockelman served as the Chief Financial Officer for National Dentex Corporation as well as the Senior Vice President/Chief Financial and Administrative Officer of the Miami Dolphins. -Manny Gonzalez (CCO), a former top (NASDAQ: PG) Procter & Gamble executive managing a team of 7,000 sales representatives in the U.S., who has direct access to every major retailer in the country. Acquisition Press Release Below: finance.yahoo.com For full disclose please visit: www.stockpicksnyc.com
DLong
by StockPicksNYC